DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

References

Drew Y.
Phase II study of olaparib plus durvalumab and bevacizumab (MEDIOLA): initial results in patients with non-germline BRCA-mutated platinum sensitive relapsed ovarian cancer. ESMO 2020.

Ann Oncol 2020;
31 (Suppl. 04) S615-S616
DOI: 10.1016/j.annonc.2020.08.953.

Download Bibliographical Data

Search in:
Access: